Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Backed by £5.5m of funding from CRUK and its partners, the hugely ambitious CRC-STARS programme - which is co-lead by Professor Simon Leedham in the Nuffeild Department of Medicine - aims to revolutionise how bowel cancer is treated.

Much has been written about the dawn of molecularly targeted cancer therapy. But for people with bowel cancer, progress has been relatively slow compared to other common cancers. And that’s despite the disease’s major molecular pathways being mapped out decades ago.

Thankfully this is starting to change, with a string of recent discoveries revealing profound new insights into bowel cancer biology.

To translate these into new treatment approaches, the £5.5m consortium of international researchers - named CRC-STARS - has recently launched, and is injecting new, and much needed, momentum into the field.

Read the full story on the CRUK website

Similar Stories

Dr Peter Wan Awarded Pancreatic Cancer UK Fellowship to Develop New Immunotherapy for Pancreatic Cancer

Dr Peter Kok-Ting Wan, PhD, postdoctoral researcher at the Department of Oncology, has been awarded a prestigious fellowship from Pancreatic Cancer UK to develop a new immunotherapy for pancreatic cancer, which has the lowest survival rate of any common cancer